micro-environmental factors that lead to the transformation from normal liver stem cells to hepatic T-ICs. We believe that etiology, microenvironmental alteration, epigenetic modification and epithelial-mesenchymal transition play a fundamental role in initiating the transformation. Strategies targeting signaling molecules critical in modulating these processes may offer a personalized therapy for HCC in the future.
INTRODUCTION
The stochastic and the hierarchic models are two hypotheses of carcinogenesis. Different from the traditional stochastic model, the hierarchic model © 1996-2015 postulates that a subpopulation of tumor-initiating cells (T-ICs), also called cancer stem cells (CSCs), gives rise to heterogeneous populations in a tumor mass. Discovery of stem cells within primary intestinal adenomas, an intestinal precancerous lesion by lineage tracing, provides direct evidence for the presence of T-ICs (1). T-ICs possess many fundamental similarities to tissue stem cells, including self-renewal, differentiation and proliferation capacity. In addition to these properties, T-ICs may evolve to subpopulations which are capable of metastasis and resistance to conventional chemotherapy. Over the past decade, T-ICs have been identified in the hematopoietic malignancies, neural, breast and other solid tumors (2) . Therapeutic strategies targeting T-ICs not only promise to eliminate cancers more efficiently, but also reduce the risk of tumor relapse and metastasis.
Hepatocellular carcinoma (HCC) is the third most lethal cancer in the world (3), while most of patients are inoperable as detected at an advanced stage. It is conceivable that approaches that could eradicate hepatic T-ICs in combination with conventional therapies will effectively improve the outcomes of HCC treatment. Several cell types in the liver have a long life-span, including liver stem/progenitor cells, hepatocytes and cholangiocytes. Evidence from human mammary epithelial cells demonstrated that differentiated normal and neoplastic non-stem cells could spontaneously convert to a stem-like state under circumstances such as inflammation, chemotherapy or irradiation, and that the conversion without genetic manipulation may involve epigenetic modifications (4) . Epigenetic modulations include histone modification, DNA methylation and chromatin remodeling, and may alter promoter activity and transcription status of individual genes; and even result in reprogramming with activation of specific transcription factors, such as pluripotent genes without any changes in the DNA sequence. It is hypothesized that once liver cells overcome specific epigenetic barriers, they may gain "stemness" or a pluripotent trait. Thus, hepatic T-ICs may originate from liver stem/progenitor cells or dedifferentiation of mature hepatocytes (5, 6) . However, how epigenetic modulations manipulate the fate of liver stem cells towards malignancy remains unknown. In-depth elucidation of epigenetic regulation in hepatic T-ICs will aid in understanding the pathogenesis of HCC and formulating potential remedies. This review focuses on the role of epigenetic regulation in the transformation from normal stem cells to T-ICs.
COMMON EPIGENETIC REGULATIONS OF HCC
Key epigenetic modifications include histone modifications, DNA methylation and chromatin remodeling, which could result in activation or repression of specific genes, reprogramming at a transcriptional level or modifications at a post-translational stage (Table 1) . Genetic and epigenetic elements interact in multiple steps during a progressive process in liver carcinogenesis. Half of primary HCC is estimated to undergo chromatin remodeling and epigenetic modifications (7).
Histone modifications
As long linear DNA forms chromosomes by wrapping histone and other proteins, histone modifications directly affect chromatin structure and function. Eight kinds of post-translational modifications including acetylation, methylation, phosphorylation, sumoylation, ubiquitination, biotinylation and ADPribosylation may occur in histones (8) . Histone acetylation or de-acetylation is the modification of multiple lysine residues catalyzed by histone acetyltransferase (HAT) and histone deacetylase (HDAC), respectively. As acetylation removes the positive charge on the histones; hence, the affinity between histone and negatively charged DNA is weakened. Therefore, the degree of histone acetylation may affect nucleosome stability and DNA accessibility (9) . HDAC-4 expression was often up-regulated in HCC specimens compared with adjacent noncancerous liver tissues (10) . Overexpression of HDAC-1 in HCC is associated with a high incidence of invasion, chemo-resistance and poor prognosis (11); whereas, inhibition of HDAC-1 suppressed cell growth, induced autophagic cell death, and reduced tumorigenic potential of hepatoma Hep3B cells (12) . Histone methylation is the modification of arginine or lysine residues in histone by the addition of methyl groups. Histone methylation status is determined by the balanced action of histone methyltransferase (HMT) and histone demethylase (HDM). The net consequence of histone methylation depends on the modification at specific lysine residues. For instance, histone H3 lysine 27 (H3K27) tri-methylation and histone H3 lysine 9 (H3K9) methylation result in transcriptional repression; whereas methylation at histone H3 lysine 4 (H3K4) causes transcriptional activation (13) . High expression of H3K27me3 was observed in 63.2 percent of HCC tissues by immunohistochemistry, and the expression levels positively or negatively correlated with poor differentiation, advanced clinical stage, vascular invasion and shortened survival duration (14) . In a different study tissue microarrays exhibited that high expression of H3K4me3 was observed in 45~50 percent of HCC specimens and was a valid predictor of reduced overall survival (15) . Histone phosphorylation occurs at serine, threonine or tyrosine residues catalyzed by a number of protein kinase, and dephosphorylated by phosphatases. Phosphorylation of histone 3 is associated with chromosome condensation and segregation (16) . In a diethylnitrosamine (DEN)-induced rodent HCC model, DEN increased phosphorylation of histone H3 at serine 10 residue within the promoter region of RNA polymerase III-dependent genes to modulate their transcription, which led to hepatocellular proliferation and transformation (17).
DNA methylation
DNA methylation occurs at the 5'-promoter region containing cytosine-guanine dinucleotide (CpG) islands in a specific gene. The demethylated status of these genes switches them into a transcriptional activation state; whereas the methylated status in general refers to transcriptional silence (18). The major DNA methyltransferases (DNMTs) consist of DNMT-1, DNMT-3a and DNMT-3b. DNMT-1 maintains the DNA methylation status during DNA replication; whereas DNMT-3a and DNMT-3b are involved in establishing de novo DNA methylation (19). Hypermethylation in CpG islands at the promoter region of tumor suppressor genes (TSG) may lead to their inactivation. In order to identify specifically altered DNA methylation, quantitative methylation analyses at the promoter regions and in a genome-wide fashion have been employed in HCC, cirrhotic and normal livers. A number of hypermethylated TSGs were selected to predict the emergence of HCC, including GSTP1, p16INK4-alpha (20) , SHP (21), HIC1, SOCS1, RASSF1, CDKN2A, APC, RUNX3, PRDM2 (22) , Lefty (23), SMPD3 and NEFH (24) . On the contrary, DNA hypomethylation increases genomic instability and occurs in the regions where it is normally hypermethylated. For instance, the human telomerase reverse transcriptase (hTERT) promoter was heavily methylated in normal liver tissue; whereas it was hypomethylated in most HCC specimens. The status of DNA methylation and histone modifications affected the ability of c-myc binding to the hTERT promoter, and regulated hTERT expression levels. Epigenetic reactivation of hTERT, which was seen in nearly 70 percent of HCC tissues, promoted the occurrence and progression of HCC (25) . Therefore, it appears that both global DNA hypomethylation and TSG hypermethylation play crucial roles in hepatic carcinogenesis by governing specific gene expression levels, such as activation of hTERT or inactivation of tumor suppressive genes.
Polycomb group protein (PGP) forms polycomb repressive complexes (PRCs) to silence differentiationtriggering genes, and maintains pluripotency of embryonic stem cells (ESCs) through H3K27me3. These developmental genes are repressed in ESCs and activated during differentiation (26) . On the other hand, PRC target genes (such as pluripotency factors) were hypermethylated in HCC as compared to non-cancerous tissues, which implied that aberrant methylation is a mechanism for hepatic T-ICs to maintain the "stemness" (27, 28) . It is known that hypermethylation may occur in an aging liver; whereas methylation in HCC exhibits in a gene-specific and disease-specific manner (29).
LIVER STEM CELLS AND PUTATIVE HEPATIC TUMOR-INITIATING CELLS

Normal liver progenitor cells and surface markers
During an embryonic development stage, the liver bud from the definite endoderm develops to bipotential liver progenitor cells (LPCc). LPCs and rodent oval cells express stem cell markers, such as epithelial cell adhesion molecule (EpCAM), oval cell marker 6 (OV-6) and neural cell adhesion molecule (NCAM), as well as hepatocyte-specific (albumin) and cholangiocytespecific markers, such as cytokeratin-19 (CK-19) (30). As a continuation of LPCs, hepatoblasts further mature to hepatocyte and cholangiocyte lineages. Hepatoblasts uniquely express the combination of EpCAM, intercellular cell adhesion molecule (ICAM-1), CK-19, albumin and alpha-fetoprotein (AFP). Mature hepatocytes and © 1996-2015 cholangiocytes no longer express stem cell markers, but only their lineage-specific markers (31). Four main (Wnt, Notch, Hedgehog and transforming growth factor-beta (TGF-beta)) signaling pathways are involved during the liver developmental stage, and they are responsible for hepatic lineage specification and morphogenesis (32). In adult human, multipotent stem/progenitor cells exist in the periductular space within the biliary tress. They express classic endodermal transcription factors (SOX-17, SOX-9, HNF-6 and SALL-4) and stem/progenitor surface markers (EpCAM, NCAM, CD133 and CXCR4) (33). These intermediate hepatobiliary cells proliferate primarily in regenerative responses when acute or chronic liver damage occurs or there is a loss of liver mass (34).
Definition of tumor-initiating cells (T-ICs) or cancer stem cells (CSCs)
To define a T-IC subpopulation from HCC tissue or a hepatoma cell line, it is crucial to have reliable cell surface markers which can be used for separating them from bulk of cancer cells. Throughout the recent studies, a group of surface markers have been selected based on following criteria: First, the expression of selected surface markers is observed in human HCC specimens or circulating tumor cells (CTCs) (35) , and the selected surface markers overlap with those for putative LPSc (36) . Second, cells from hepatoma with positive markers exhibit higher tumorigenicity ability in vitro and in vivo than those with negative markers. Moreover, further serial transplantation of hepatoma cells with the positive markers from tumor xenografts could continuously generate tumors in the second and third batch of immunodeficient mice. Third, hepatoma cells with the positive markers not only possess self-renewal capacity, but also are capable of differentiating into both positive and negative marked cells. Fourth, hepatoma cells with the positive markers express genes important for the proliferation, self-renewal and differentiation of stem cells (37) . Fifth, blockage of these markers could significantly inhibit cellular invasion, spheroid formation and tumorigenicity. According to these standards, CD133 (38) , CD90 (39, 40) and EpCAM (41, 42) have been chosen as useful markers of liver T-ICs. However, the origins and definition of T-ICs are not well specified, and studies with different patient specimens, hepatoma cell lines or primary tumors from animal models may have a variety of cell sources which could potentially become the origins for T-ICs under particular circumstances as listed in Table 2 .
Side subpopulation
Another subpopulation not in full accordance with above criteria is side population (SP) cells. These cells are defined by their ability to efflux the DNA-binding dye Hoechst 33342 through an adenosine triphosphate (ATP)-binding cassette (ABC) membrane transporter associated with multidrug resistance (43). SP cells were found to display higher proliferation activity, apoptotic tolerance and oncogenic capacity in serial NOD-SCID xenograft transplantation than non-SP cells (44). Hepatic progenitor markers (CD44, EpCAM and Bmi) were upregulated in these SP cells. SP cells isolated from a myc-driven mouse HCC model were resistant to chemotherapy (doxorubicin and paclitaxel) through multidrug resistance gene 1 (MDR1) transporter (45). It is claimed that T-ICs are a subset of the SP cells and contribute to resistance and relapse after chemotherapy or irradiation (45). However, SP cells that have stem cell potential and generate all cell types in a tumor usually do not have the same surface marker profile as T-ICs. Whether they are the same subpopulation as those selected by T-ICs markers need to be verified.
ROLE OF ETIOLOGY AND MICROENVIRONMENTAL CHANGES IN EPIGENETIC MODIFICATIONS
HCC is heterogeneous in terms of oncogenic pathways, molecular regulation, progressive and metastatic capability due to the fact that it derives from various base diseases. Therefore, tumors from various individuals may arise from a different cell of origin. Undoubtedly, etiology plays an important role in epigenetic modulation of hepatocytes from which HCC may be derived. Viral infection, inflammation and oxidative stress could change the microenvironment niche and induce epigenetic instability, and the latter in turn fosters the appearance of tumor-initiating cells.
Hepatitis B viral infection
Hepatitis B viral infection is the leading cause of HCC in the Asian and African regions and the mechanisms of HBV-associated HCC have been studies for decades, however they largely remain to be poorly understood. Recent studies revealed that the HBV X protein (HBx) is responsible for the aberrant epigenetic regulation, and resulted in a malignant transformation. HBx not only functioned as a transcription factor to enhance the expression of DNMT-1, DNMT-3A1 and DNMT-3A2, which in turn repress host tumor suppressor genes by hypermethylation of their promoters (46), but also upregulated tumor-initiating genes through hypomethylation, such as aldehyde dehydrogenase 1 (ALDH-1), plasma retinol-binding protein precursor Table 2 . Origins of hepatic T-ICs Moreover, HBx downregulated the chromatin remodeling protein suppressor of zeste 12 homolog (Suz12) and zinc finger protein, MYM-type 2 (Znf198) (48). Suz12 is a component of the polycomb repressive complexes PRC2 which mediates H3K27 trimethylation (49); whereas Znf198 stabilizes the lysine-specific demethylase 1-corepressor of RE1-silencing transcription factor histone deacetylase-1 (LSD1-CoREST-HDAC-1) complex, and the latter removes histone modifications affecting transcriptional activation (50) . Repression of Suz12 enhanced the EpCAM expression and promoted cell proliferation (51) . Immunohistochemical analysis of HBV-infected HCC tissue showed that HBx was associated with upregulation of "stemness" transcription factors: Oct-4, Nanog and KLF-4, as well as "stemness" marker: EpCAM. Consistent with stem cell behavior, HBx-transfected HepG2 cells displayed pronounced tumorigenic ability in vitro and in vivo. Thus, HBxinduced epigenetic alterations, including aberrant histone modifications, DNA methylation and critical transcription factors, such as Suz12 and Znf98 or a repressor, facilitate the differentiation of HBV-infected cells towards hepatic T-ICs.
Hepatitis C viral infection
Hepatitis C virus is the second to HBV that causes chronic hepatitis and an increased risk for HCC. In a chimeric mouse model, a long period of HCV infection elicited methylation of 237±110 genes, some of which were increased in HCC specimens compared to noncancerous tissues (52) . Wnt/beta-catenin signaling plays an important role in the development, cell differentiation or proliferation and metabolism of the liver. Epigenetic modification of a Wnt antagonist, secreted frizzled related proteins (SFRP), may result in abnormal activation of Wnt signaling. The HCV core protein directly increased the expression and binding of DNMT-1 and HDAC-1 to the transcriptional start site of the SFRP-1 promoter, which led to hypermethylation of SFRP-1 and silence of its expression, and eventually the accelerated growth and aggressiveness of HCC (53) . In HCV core gene transgenic mice fed alcohol model, enhanced DNA hypomethylation, histone acetylation and demethylation elicited the generation of TLR4-Nanog dependent T-ICs (54). Thus, the HCV core protein directly or indirectly affects epigenetic alterations that may expedite the oncogenic transformation in the host cells.
Chronic inflammation
Chronic inflammation enables hepatic carcinogenesis by induction of mutations and chromosomal instability, and by the release of a wide range of cytokines, such as TNF-alpha, interleukins and TGFbeta, that mediate interactions between inflammatory pathways and epigenetic modifications (55) . Among these cytokines, TGF-beta is responsible for suppressing the proliferation of LPCs to acquire characteristics of T-ICs (56) . In human cirrhotic liver, increased TGF-beta levels were correlated with OV-6-positive LPCs that co-express CD133, CD90 and EpCAM. After treatment with TGF-beta, rat pluripotent LPC-like WB-F344 cells constantly exhibited mesenchymal characteristics and expressed more CD90 and CD133 than control cells. Moreover, TGF-beta-1-treated cells generated xenograft tumors in NOD-SCID mice. TGF-beta-1 increased CD133 expression by inducing demethylation of the CD133 promoter-1. After TGF-beta-1 bound to the TGF-beta receptor, both Smad2 and Smad3 were phosphorylated, and they formed a hetero-complex. The latter was translocated into the nucleus and suppressed DNMT1 and DNMT-3-beta expression. Decreased DNMT-1 and DNMT-3-beta finally led to demethylation of the CD133 promoter-1(57). In albumin-cre transgenic mice lacking p53 (Trp53 KO ) model, inactivation of p53 and TGF-beta receptor II reduced the phosphorylation of downstream Smad3 and extracellular signal-regulated kinase (ERK)1/2, which in consequence down-regulated TGFbeta target genes. Thus, it is not difficult to understand that the disruption of the TGF-beta pathway triggered the emergence of T-IC, and accelerated HCC progression through p53 inactivation (58).
Oxidative stress
Sustained HBV or HCV infection, alcohol liver toxicity or NAFLD causes chronic liver damage and oxidative stress, and eventually HCC develops in these base diseases. Excess of endogenous and exogenous reactive oxygen species (ROS) results in DNA damage and alteration of the methylation status. H 2 O 2 induced hypermethylation of the E-cadherin promoter through upregulation of snail expression. Snail elicited E-cadherin hypermethylation through recruiting DNMT-1 and HDAC-1 (59). Besides inactivation of TSGs through DNA hypermethylation, ROS activates a positive feedback loop that exacerbates a chronic state of inflammation. As mentioned above, chronic liver inflammation initiates epigenetic instability and in turn results in abnormal hepatocellular proliferation and oncogenic transformation in an inflammatory microenvironment where oxidant stress is constantly overwhelmed, such as NASH, alcoholic liver injury, ion-over load and drug toxicity, even without cirrhosis (60).
EPIGENETIC MODIFICATION FACILITATES THE TRANSFORMATION TOWARDS T-ICS
Overexpression of four transcription factors (Oct-4, Sox-2, KLF-4 and C-myc) could reprogram fibroblasts into induced pluripotent stem cells (iPSC) (61) . Similarly, introduction of these four factors into gastrointestinal cells may reprogram them into a pluripotent state and sensitize them to a malignant transformation (62). In a carcinogeninduced AH130 hepatoma model, o-aminoazotoluene exposure accomplished a series of reprogramming and © 1996-2015 tumorigenesis step-wisely. Eventually 100 percent of AH130 cells expressed immature marker CD133, and three transcription factors: Nanog, KLF-4 and c-myc (63). Expression of these stemness and oncogenic genes was probably the primary intrinsic force driving the oncogenic transformation. Thus, an initiating event such as viral infection, inflammation or drug toxicity, may activate the "epigenetic switch" that resets the long-term memory of hepatocytes or liver stem cells, and provoke their transformation to hepatic T-ICs. The following are examples of how epigenetic modifications lead to oncogenic reprogramming towards T-ICs.
Histone ubiquitination and acetylation
As a core element of PRC1, B lymphoma moloney murine leukemia virus insertion region 1 homolog (Bmi-1) plays an important role in the selfrenewal of LPCs. SALL-4 is one of classic endodermal transcription factors, and causes upregulated expression of LPC markers (EpCAM, CK19 and CD44), and enhanced spheroid formation capacity of EpCAM + cells. It was found that its activity was mediated through modification of HDAC activity, because HDAC inhibitors suppressed the proliferation of SALL-4 + cells (67) . In addition to interaction with HDAC-1, SALL-4 could suppress target gene expression through direct interaction with DNMTs and mediate activity of the gene product, HDAC-1 (68).
In summary, it appears that pluripotent transcription factors, such as Nanog, Sox-2, Oct-4 or SALL-4, affect the fate of genetic reprogramming by regulating activity of specific target genes via the activity change of HDAC-1 or DNMTs at epigenetic levels.
DNA methylation and demethylation
Global genomic DNA hypomethylation has been observed as a frequent event in various cancers. Methylation of long interspersed nucleotide element-1 (LINE-1) was reported to represent as a surrogate marker for the global DNA methylation and a molecular marker of prognosis for many solid tumors (69, 70) . It is demonstrated in the tamoxifen-induced rat hepatic carcinogenic model that exposure to tamoxifen resulted in LINE-1 hypomethylation and increased expression of LINE-1 and c-myc. Tamoxifen-containing diet up-regulated regenerative cell proliferation of rat hepatocytes (71) . In human HCC specimens, LINE-1 demethylation correlated to elevated CD133 expression and shorter cumulative survival (72) . Therefore, it is speculated that LINE-1 demthylation could be a trigger for the transformation of mature hepatocytes to oncogenic T-ICs in this model.
Epigenetic modification of transcription factors affecting pluripotency
Epigenetic regulation of transcription factors, such as Nanog, Oct-4, Sox-2, c-Myc and KLF-4 provokes pluripotency of cancer cells. Hypomethylation of the Nanog promoter was observed in primary HCC specimens and CD133 +high colorectal carcinoma cells. In accordance with this, the upregulation of Nanog was associated with demethylation of the Oct-4 promoter and enhanced Oct-4 mRNA expression (73) . Oct-4 overexpression in turn activated the Oct-4-AKT-ABCG2 pathway, and the latter eventually led to chemo-resistance. Furthermore, these chemo-resistant HCC cells displayed stem cell features (74) . Thus, demethylation of pluripotent genes contributed to epigenetic reprogramming and initiation of T-ICs.
Aberrant hedgehog signaling in hepatic T-ICs
Hedgehog (Hh) signaling governs the fate of progenitor cells during embryogenesis, and helps orchestrate liver development and repair. Reactivation of Hh in adulthood occurs during liver regeneration, inflammation, fibrogenesis and vascular remodeling (75) (76) (77) . In NAFLD, the level of Hh signaling activation in the liver tissue paralleled with the extent of steatohepatitis and fibrosis. The level of Hh signaling activity was also strongly correlated with clinical parameters of metabolic syndrome (age, BMI, waist circumference, log HOMA-insulin resistance and hypertension) (78) . A retrospective analysis demonstrated that 65 percent (20/31) of individuals with metabolic syndrome developed HCC without significant fibrosis (79) , which implied that the Hh signaling may be of paramount importance in carcinogenesis in these patients. The Hh signaling had been identified to be crucial for the maintenance of T-ICs in multiple myeloma and myeloid leukemia (80, 81) . In HBV/HCV-associated HCC, Hh-responsive cells, including T-ICs, expanded during cirrhosis and HCC (82) . Hypermethylation of the Hh-interacting protein (HHIP) gene, the negative regulator of Hh signaling, led to down-regulation of the HHIP at a transcriptional level in hepatoma cells and HCC tissues. Based on growing evidence, it appears to be most likely that hypermethylation elicited activation of the Hh pathway, which in turn stimulated liver transformation and HCC development (83).
Abnormal activation of Wnt-beta-catenin signaling activity
In active necrotic inflammation, a strong activation of the Wnt signaling stimulated the proliferation of LPCs (84) . In Huh7 cells and primary HCC tissues, OV6-positive progenitor cells expressed high levels of β-catenin and displayed increased proliferation capacity. General activation of the Wnt/beta-catenin pathway has been observed in one third of HCCs, and activation of the Wnt/ beta-catenin pathway provoked expression of EpCAM, enhanced self-renewal potential and chemotherapy resistance (85, 86) . The increased Wnt/beta-catenin signaling in HCC samples and hepatoma cell lines was caused by hypermethylation and histone H3 lysine 27 trimethylation of Wnt antagonists, which lead to reduced expression of Wnt antagonists (87, 88) . Epigenetic down-regulation of the Wnt signaling antagonists would in turn lead to hyperactivation of the Wnt/beta-catenin pathway into a positive feedback loop, and consequently enhanced proliferation of HCC.
ROLE OF MICRORNAS IN MODULATING EPIGENETIC STATUS
miRNAs are a class of non-coding RNAs that regulate gene expression by binding to 3'-untranslated regions (UTR) of target mRNAs. Tremendous efforts have been dedicated to identify specific miRNAs that play oncogenic or suppressive roles in HCC (89, 90) . In addition to functioning as translational repressors, miRNAs may regulate the expression of target genes through interaction with epigenetic components. Enhancer of zeste homolog 2 (EZH2), the H3K27 trimethylating enzyme, was upregulated in 69.5 percent (41/59) of primary HCCs, and multiple tumor-suppressor miRNAs were epigenetically silenced by EZH2. miRNAs that were silenced in this fashion included miR-139-5p, miR-125b, miR-101, let-7c and miR-200b (102) . In addition to interaction with the H3K27 tri-methylating enzyme, miR-152 targeted 3'UTR of DNMT-1 and caused increased hypermethylation of two tumor suppressor genes (GSTP1 and CDH1) in HBV-related HCC (92) . Thus, miRNAs not only modulate target gene expression at translational levels, but also affect oncogenes or tumor suppressive genes at transcriptional levels via epigenetic modification. The following is a list of miRNAs which alter expression of target oncogenic or pluripotent genes through epigenetic modulation.
miR-148a
MiR-148a is identified as a liver-specific miRNA highly expressed in mature hepatocytes, and frequently down-regulated in human HCC lines and tissues. In mouse fetal hepatoblasts, miR-148a facilitated hepatic differentiation through DNMT-1 inhibition. MiR-148a directly regulated DNMT-1 expression by complementary binding to its 3'-UTR element. In Hepa 1-6 hepatoma cells, miR-148a suppressed invasive properties of HCC cells by indirectly inhibiting hepatocyte growth factor receptor (c-Met) (103) . As IL-6 increased the expression of DNMT-1 through miR-148a in human cholangiocarcinoma cell lines, miR-148a provides a link between inflammation-associated cytokine and oncogenesis in cholangiocarcinoma (104).
miR-122
MiR-122 is a critical miRNA abundant in the liver, and is involved in hepatic carcinogenesis, lipid metabolism and HCV replication. MiR-122 was highly enriched in differentiated human hepatocytes, but its expression decreased in hESCs and HCC. miR-122 functions as a modulator to suppress self-renewal and proliferation of hESCs and HCC through inhibiting the expression of Pkm2. In human primary hepatocytes, the promoter of miR-122 was hypo-methylated, which facilitated RNA polymerase II to bind and initiate transcription. Whereas, hypermethylation of the same region in hESCs and HCC made it impossible for RNA polymerase II to bind and in turn inhibited miR-122 transcription (105) . Treating the HepG2 and Hep3B cells with a DNA methylation inhibitor (5'aza-2'deoxycytidine) restored the expression of miR-122. In addition, peroxisome proliferator activated receptor-gamma (PPAR-gamma) and retinoid X receptor alpha (RXRalpha) complex could bind to the miR-122 promoter and enhance its transcription (106).
miR-214
The attenuated expression of miR-214 was often observed in HCC tissue and highly associated with tumor early recurrence. miR-214 directly targeted 3'-UTR sequence of EZH2 and β-catenin mRNA, and inhibited their protein expression. Knockdown miR-214 expression increased EpCAM + stem-like HLE cells through activating β-catenin signaling. Thus, miR-214 induced stem-like features of HCC, and may be closely involved in early tumor recurrence (107) . © 1996-2015
In summary, a group of miRNAs are oncogenic and their expression is often suppressed in hepatic malignancy, whereas other miRNAs act as tumorsuppressors by inhibiting expression of genes involved in oncogenesis. These tumor-suppressive miRNAs are often down-regulated in HCC. The influence of miRNAs on epigenetic changes depends on the target gene specificity of individual miRNAs, and their effects range from differentiation, aggressive behavior, drug resistance to metastasis. The dissection and verification of each miRNA function in these processes will enhance our understanding of critical but complicated interplay of multiple miRNAs in oncogenesis, metastasis or relapse.
EPITHELIAL MESENCHYMAL TRANSITION AND EPIGENETIC MODIFICATIONS
Epithelial-mesenchymal transition (EMT) is defined as a process by which epithelial cells lose cell adhesion and baso-apical polarity, meanwhile acquire mesenchymal features. The molecular characteristic of EMT is the down-regulation of E-cadherin and upregulation of mesenchymal markers, including N-cadherin, vimentin and fibronectin. EMT occurs in such cases as normal organ development and embryogenesis, tissue damage, inflammation, fibrosis and tumor metastasis (108) (109) (110) . Expression of EMT-related transcription factors, such as snail and twist, was upregulated in scirrhous HCC, a rare variant of HCC which is characterized by abundant fibrous stroma and expression of several LPC markers (such as EpCAM and CK19) (111) (112) . CTCs isolated from a mouse HCC model exhibited an EMT status, and increased expression of HGF and its receptor (c-Met) was demonstrated in these cells. Demethylation of HGF and c-Met increased expression of HGF, which in turn switched CTC to display EMT characters, increased tumorigenicity and metastatic potential (113) . Increasing matrix stiffness drove HCC cells to acquire the mesenchymal properties and to be resistant to chemotherapy in vitro. On contrary, a soft environment enhanced the colony initiating capacity of chemotherapy-treated cells, which was associated with increased "stemness" gene expression, including CD133, CD44, OCT-4 and NANOG (114) . In summary, EMT facilitates disseminated tumor cells to emigrate from the primary tumor microenvironment and to establish micrometastases at distal sites.
CONCLUSIONS AND PERSPECTIVES
Pathogenic processes, such as viral infection, inflammation, oxidative stress and drug toxicity alter the micro-environment in the liver and elicit abnormal epigenetic modifications, including histone acetylation or deacetalytion, and DNA hyper-or hypomethylation. In these processes, miRNAs participate in the regulation of their target gene expression in addition to their translational repression. The aberrant epigenetic modifications facilitate the transformation of normal LPCs to hepatic T-ICs in the response to changes of the microenvironmental niche; whereas the activation of "stemness" transcription factors, such as KLF-4, Nanog, Oct-4, Bmi-1 or Sox-2 or 17, as well as oncogenic signaling molecules, such as TGF-beta-1, hedgehog, beta-catinen, met or c-myc results in a genetic/epigenetic reprogramming. These signaling molecules may be considered as intrinsic forces in driving the malignant transformation and the appearance of T-ICs. Although the effects and regulation underlying the complex interplays of each epigenetic modification on histone and other nuclear proteins, signaling molecules remain largely unexplored, the net consequence is the occurrence and expansion of T-ICs in various disease bases. These T-ICs probably are the origins of many cell types in a tumor mass. It is also conceivable that T-ICs may be induced during various stages of cancer development and treatment, and these T-ICs are mainly responsible for chemo-or radiation-resistance, and are believed to be the cell origins for relapse (34). EMT has been suggested as a critical phenotypic change for cancer cells to be chemoresistant and metastatic. Given the fact that the markers used for T-IC isolation and characterization are different from various studies, it is understandable that T-ICs are not the same from different disease bases or at various stages of HCC development and progression. Whether a unique T-IC population will be identified for HCC depends on the success of a large cohort of clinical trials by multi-center collaboration with a defined combination of surface markers, such as CD133, CD90 or EpCAM, etc. (115, 116) . It is foreseeable that such a trial aimed at defining the most representative "hepatic T-ICs" by multidisciplinary investigators is warranted in the near future. For a better understanding of this complex interplay, a schematic illustration is shown as Figure 1. On the other hand, the identification of critically abnormal epigenetic modificatio`ns in HCC development and progression offers molecular targets for fine-tuning therapeutics and personalized therapy strategies. Increasing evidence demonstrates that a therapeutic strategy targeting a single pathway is insufficient to eliminate HCC. Due to critical roles of epigenetic modulations on hepatic T-IC function and differentiation, the epigenetic therapy may point to a novel direction in the development of next generation of therapeutics. For instance, as a selfrenewal regulator, EZH2, modulates the self-renewal and © 1996-2015 differentiation of hepatic stem cells. 3-Deazaneplanocin A (DZNep), an EZH2 pharmacological inhibitor, decreased EpCAM + T-IC subpopulation and suppressed tumorigenesis in NOD-SCID mice (117) . In this context, the use of EZH2 inhibitors, such as an S-adenosylhomocysteine hydrolase inhibitor, DZNep, might be a promising strategy through targeting hepatic T-ICs (117) . A demethylating agent, zebularine, increased self-renewal and tumorigenicity of low density HCC cells. But treated HCC cells at high density with zebularine decreased self-renewal and tumorigenicity. Thus, the dual effect of this DNMT1 inhibitor on T-ICs characters depended on HCC cellular density (118) . A multicenter phase I/II trial assessed the efficacy of a histone deacetylase inhibitor, belinostat, on unresectable HCC. The rate of partial response and stable disease of 42 patients was 2.4 and 45.2 percent, respectively. The progression-free and overall survival was 2.6 and 6.6 months, respectively. Epigenetic therapy with belinostat displayed well-tolerated and disease stabilization, and more studies are needed to further determine the efficacy and benefits with belinostat treatment in HCC patients (119) . Obviously, questions remain regarding whether epigenetic therapy alone or in combination with conventional chemotherapy will be more effective in eradicating T-IC than currently available adjuvant therapeutics for the improvement of therapeutic outcome.
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